Biotech News

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

Context Therapeutics (CNTX)Context TherapeuticsCompany update

PHILADELPHIA, July 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the Company was added to the small-cap

Related news

CNTXContext Therapeutics2026-11-10 21:17 EST

Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress

PRLDPrelude Therapeutics2026-11-16 12:01 EST

Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

CGEMCullinan Therapeutics, Inc.2026-11-04 14:14 EST

Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

CMPXCompass Therapeutics2026-10-24 08:15 EST

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

NRIXNurix Therapeutics2026-11-11 12:00 EST

Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer

FATEFate Therapeutics2026-11-10 12:00 EST

Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy

CGEMCullinan Therapeutics, Inc.2026-11-09 15:00 EST

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

FATEFate Therapeutics2026-11-05 12:00 EST

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

Context Therapeutics

Solid-Tumor T-Cell Engagers Context Therapeutics develops bispecific antibodies that bind a tumor antigen and CD3 to recruit T cells against solid tumors. CTIM-76 CTIM-76 targets Claudin 6 and CD3. It is the company's lead Phase 1 program in tumors expressing the developmentally restricted CLDN6 antigen. CT-95 CT-95 is a...

Recent company news

Stock data

Close
0.17 USD
Market cap
222.35M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States